Over the past decade, CRISPR has become as much a verb as it is an acronym,
transforming biomedical research and providing entirely new approaches for dissecting all …

The CRISPR-Cas9 RNA-guided DNA endonuclease has contributed to an explosion of
advances in the life sciences that have grown from the ability to edit genomes within living …

DNA mismatch repair deficiency (MMRd) is associated with a high tumor mutational burden
(TMB) and sensitivity to immune checkpoint blockade (ICB) therapy. Nevertheless, most …

Adoptive therapy using chimeric antigen receptor-modified T cells (CAR-T cells) is effective
in hematologic but not epithelial malignancies, which cause the greatest mortality. In breast …

The CD155/TIGIT axis can be co-opted during immune evasion in chronic viral infections
and cancer. Pancreatic adenocarcinoma (PDAC) is a highly lethal malignancy, and immune …

Approximately 30% of human lung cancers acquire mutations in either Keap1 or Nfe2l2,
resulting in the stabilization of Nrf2, the Nfe2l2 gene product, which controls oxidative …

For tumors to progress efficiently, cancer cells must overcome barriers of oxidative stress.
Although dietary antioxidant supplementation or activation of endogenous antioxidants by …

Treating KRAS-mutant lung adenocarcinoma (LUAD) remains a major challenge in cancer
treatment given the difficulties associated with directly inhibiting the KRAS oncoprotein. One …

Immune evasion is a hallmark of cancer and therapies that restore immune surveillance
have proven highly effective in cancers with high tumor mutation burden (TMB)(for example …

Summary Interferon-γ (IFN-γ)-mediated adaptive resistance is one major barrier to improving
immunotherapy in solid tumors. However, the mechanisms are not completely understood …